Actively Recruiting
Phase 2 Study of First-Line Chemo-Immunotherapy Followed by Pembrolizumab and Olaparib Maintenance in Extensive-Stage Small-Cell Lung Cancer
Led by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Updated on 2025-06-24
60
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination treatment approach for patients with untreated Extensive-Stage Small-Cell Lung Cancer ES SCLC, a very aggressive cancer with limited survival and treatment options. This phase 2 trial focuses on an induction phase using chemo-immunotherapy followed by a maintenance phase with pembrolizumab and olaparib. The study aims to improve progression-free survival and explore molecular features related to the disease and treatment response. Patients will initially receive pembrolizumab combined with a platinum-based chemotherapy cisplatin or carboplatin plus etoposide for four cycles in the induction phase. If their disease responds or remains stable, they will continue to a maintenance phase receiving pembrolizumab plus olaparib until disease progression or for a maximum of 35 cycles. The study includes tissue sample collection before and during treatment to analyze molecular characteristics. Participants will be monitored closely through clinical assessments and laboratory tests, including immune and genetic marker analyses. The primary outcome measured is progression-free survival, with secondary outcomes including response rates, overall survival, and safety events. The total study duration includes 24 months of patient enrollment and 12 months of follow-up after the last patient is enrolled, allowing researchers to gather comprehensive data on treatment impact and safety.
CONDITIONS
Brief Title
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
Research Team
O
Oriana Nanni
B
Bernadette Vertogen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here